Publications
Stone S, McPherson JP, Kulkarni RP, Young A. The impact of concomitant medications on treatment outcomes in patients with cancer receiving immune checkpoint inhibitors. Nat Rev Cancer. 2026 Feb;26(2):137-158. doi: 10.1038/s41568-025-00890-z. Epub 2025 Dec 3. PMID: 41339541.
Fey RM, Billo A, Clister T, Doan KL, Berry EG, Tibbitts DC, Kulkarni RP. Personalization of Cancer Treatment: Exploring the Role of Chronotherapy in Immune Checkpoint Inhibitor Efficacy. Cancers (Basel). 2025 Feb 21;17(5):732. doi: 10.3390/cancers17050732. PMID: 40075580; PMCID: PMC11899640.
Fey RM, Nichols RA, Tran TT, Vandenbark AA, Kulkarni RP. MIF and CD74 as Emerging Biomarkers for Immune Checkpoint Blockade Therapy. Cancers (Basel). 2024 May 4;16(9):1773. doi: 10.3390/cancers16091773. PMID: 38730725; PMCID: PMC11082995.
Garrison Z, Clister T, Bleem E, Berry EG, Kulkarni RP. Comparison of Immunotherapy versus Targeted Therapy Effectiveness in BRAF-Mutant Melanoma Patients and Use of cGAS Expression and Aneuploidy as Potential Prognostic Biomarkers. Cancers (Basel). 2024 Mar 1;16(5):1027. doi: 10.3390/cancers16051027. PMID: 38473384; PMCID: PMC10931246.
Clister T, Fey RM, Garrison ZR, Valenzuela CD, Bar A, Leitenberger JJ, Kulkarni RP. Optimization of Tissue Digestion Methods for Characterization of Photoaged Skin by Single Cell RNA Sequencing Reveals Preferential Enrichment of T Cell Subsets. Cells. 2024 Jan 31;13(3):266. doi: 10.3390/cells13030266. PMID: 38334658; PMCID: PMC10854603.
Van Buren I, Madison C, Kohn A, Berry E, Kulkarni RP, Thompson RF. Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy. JAMA Netw Open. 2023 Oct 2;6(10):e2340695. doi: 10.1001/jamanetworkopen.2023.40695. PMID: 37906189; PMCID: PMC10618850.
Garrison ZR, Hall CM, Fey RM, Clister T, Khan N, Nichols R, Kulkarni RP. Advances in Early Detection of Melanoma and the Future of At-Home Testing. Life (Basel). 2023 Apr 9;13(4):974. doi: 10.3390/life13040974. PMID: 37109503; PMCID: PMC10145469.
Garrison Z, Chang M, Hornick N, Yu WY, Cheng JB, Kulkarni RP. A Novel Potential Role for Monocytes Revealed by Single Cell Analysis of Immunotherapy Induced Immune Related Adverse Events. Cancers (Basel). 2022 Nov 2;14(21):5407. doi: 10.3390/cancers14215407. PMID: 36358824; PMCID: PMC9657437.
Seervai RNH, Sinha A, Kulkarni RP. Mechanisms of dermatological toxicities to immune checkpoint inhibitor cancer therapies. Clin Exp Dermatol. 2022 Nov;47(11):1928-1942. doi: 10.1111/ced.15332. Epub 2022 Sep 11. PMID: 35844072.
Fankhauser R, Chang M, Garrison Z, Berryman R, Lucero OM, Fuiten A, DePatie N, Seifert H, Kulkarni RP. Single-Cell Identification of Melanoma Biomarkers in Circulating Tumor Cells. Cancers (Basel). 2022 Oct 8;14(19):4921. doi: 10.3390/cancers14194921. PMID: 36230844; PMCID: PMC9564060.
Garrison Z, Hornick N, Cheng J, Kulkarni RP. Circulating biomarkers of response to immunotherapy and immune-related adverse events. Expert Rev Mol Diagn. 2022 Sep;22(9):855-865. doi: 10.1080/14737159.2022.2130688. Epub 2022 Oct 7. PMID: 36193802.
Kulkarni RP, Yu WY, Leachman SA. To Improve Melanoma Outcomes, Focus on Risk Stratification, Not Overdiagnosis. JAMA Dermatol. 2022 May 1;158(5):485-487. doi: 10.1001/jamadermatol.2022.0097. PMID: 35385059.
Fuiten AM, Fankhauser RG, Smit DJ, Stark MS, Enright TF, Wood MA, DePatie NA, Pivik K, Sturm RA, Berry EG, Kulkarni RP. Genetic analysis of multiple primary melanomas arising within the boundaries of congenital nevi depigmentosa. Pigment Cell Melanoma Res. 2021 Nov;34(6):1123-1130. doi: 10.1111/pcmr.12979. Epub 2021 May 7. PMID: 33884765.
Lee EY, Kulkarni RP. Circulating biomarkers predictive of tumor response to cancer immunotherapy. Expert Rev Mol Diagn. 2019 Oct;19(10):895-904. doi: 10.1080/14737159.2019.1659728. Epub 2019 Sep 10. PMID: 31469965; PMCID: PMC6773262.
Dhar M, Wong J, Che J, Matsumoto M, Grogan T, Elashoff D, Garon EB, Goldman JW, Sollier Christen E, Di Carlo D, Kulkarni RP. Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. Sci Rep. 2018 Feb 7;8(1):2592. doi: 10.1038/s41598-018-19245-w. PMID: 29416054; PMCID: PMC5803213.
Shen J, Chang J, Mendenhall M, Cherry G, Goldman JW, Kulkarni RP. Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management. Ther Adv Med Oncol. 2018 Jan 22;10:1758834017751634. doi: 10.1177/1758834017751634. PMID: 29383039; PMCID: PMC5784551.
Circulating biomarkers predictive of tumor response to cancer immunotherapy. Expert Reviews of Molecular Diagnostics, 10:1-10. Lee EY, Kulkarni RP. (2019)
Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic cancer. Scientific Reports, 8(1):2592. Dhar M, Wong J, Che J, Matsumoto M, Sollier E, Grogan T, Elashoff D, Garon EB, Goldman JW, Di Carlo D, Kulkarni RP. (2018)
Editor's Choice for Science Translational Medicine
Undressing drug reactions, one cell at a time. Science Translational Medicine, 12(529):eaba9015. Kulkarni RP. (2020)
Probiotics leap from gut to blood. Science Translational Medicine, 11(521):eaaz9763. Kulkarni RP. (2019)
Later is better: Corticosteroids selectively suppress early memory T cells. Science Translational Medicine, 11(513):eaaz3711. Kulkarni RP. (2019)
Better living through your gut microbes. Science Translational Medicine, 11(505):eaay7700. Kulkarni RP. (2019)
Coaxing cancer control by modulating COX-2. Science Translational Medicine, 11(497):eaax9566. Kulkarni RP. (2019)
Continuously capturing circulating cancer cells. Science Translational Medicine, 11(489):eaax1730. Kulkarni RP. (2019)